Addition of dordaviprone strengthens Jazz’s late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need
Jazz Pharmaceuticals announced the successful completion of its acquisition of Chimerix, Inc. for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz.
Health Technology Insights: ERPHealth partners with Penn State to help prevent substance use disorder
“Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs,” said Bruce Cozadd, chairman and chief executive officer of Jazz. “Dordaviprone has the potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and offers a promising near-term commercial opportunity, if approved. We are excited to welcome Chimerix’s talented team as we collectively continue to advance dordaviprone, leveraging our development and commercial capabilities to deliver this therapy to patients as soon as the second half of this year.”
The addition of dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, further diversifies and adds near-term commercial opportunity to Jazz’s oncology pipeline. Dordaviprone is currently under Priority Review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date set for August 18, 2025. If approved in the U.S., the therapy may be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Dordaviprone is also being studied in the ongoing Phase 3 ACTION trial to evaluate its use in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment, potentially extending its use into the first-line setting.
Health Technology Insights: The Future of AI & Electrophysiology Takes Center Stage at Heart Rhythm 2025 with Vektor Medical
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
